The global market for the next generation drug conjugates is expected to grow at a compounded annual growth rate (CAGR) of more than 20% during the forecast period. The next generation drug conjugates, owing to their non-immunogenic nature, better clinical profile, structural stability, limited side effects, targeted delivery of payload, deeper cellular penetration, and permeability, have emerged as the viable targeted therapeutics for rare disease indications, including cancers.